• 한국임상수의학회지
• /
• 제27권4호
• /
• pp.453-456
• /
• 2010

생후 1개월령의 0.9 kg수컷 삽살개가 식욕부진, 배뇨곤란, 기립곤란, 침울을 주증으로 병원에 내원하였다. 신체검사에서는 빈맥, 저체온증, 점막창백 소견을 보였다. 혈액검사에서는 백혈구증가증과 빈혈소견이 있었고, 혈청생화학검사에서는 BUN (57.3 mg/dl)과 $NH_3$ ($584\;{\mu}g/dl$)의 증가, 알부민과 나트륨 및 칼륨의 저하소견을 보였다. 뇨검사에서는 혈뇨, 단백뇨, 당뇨, 세균뇨(Staphylococcus spp.)와 인산암모늄마그네슘결정뇨의 소견을 보였다. 방사선 검사에서는 확장된 방광과 요도내 2 mm크기의 결석을 발견할 수 있었다. 요도절개술로 요도내 결석을 제거하였고, 수술 후 환자는 정상적으로 회복되었다. 본 케이스는 요소분해효소 생산 세균의 감염과 고암모니아증을 동반한 어린 삽살개에서 스트루바이트 결석증 발생하였음을 보고한다.

• Journal of Korean Neurosurgical Society
• /
• 제30권sup2호
• /
• pp.259-265
• /
• 2001

Objectives : Spontaneous intracerebral hemorrhage(S-ICH) is generally considered to be a mon-ophasic event. But some patients with ICH continued to bleed even after hospitalization. In order to evaluate the rebleeding and growth factor of hematoma in small volume S-ICH, 125 cases of S-ICH were reviewed retrospectively. Methods : We assesed age, sex, initial mental state, location of hemorrhage, systolic and diastolic blood pressure, blood pressure patterns, hematologic profile, trauma and stroke history, alcohol consumption and smoking history. Two subgroups-rebleeding groups versus no rebleeding groups-were compared, in terms of data analysis, with student T-test and chi-square test. Results : Substantial growth in the volume of S-ICH occurred in 21 cases(16.8%)-putamen(7 cases), thalamus(6 cases), subcortex(5 cases), cerebellum(2 cases), pons(1 case)-of the 125 patients. There was no significant difference in any of the parameters except initial systolic blood pressure(p=0.037) when patients with and without rebleeding were compared. Conclusion : The rebleeding and growth of the small volume S-ICH was related to the markedly elevated initial systolic blood pressure(${\geq}180mmHg$) and labile pattern of blood pressure.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권6호
• /
• pp.2355-2359
• /
• 2015

Background: Combination chemotherapy of 5 fluorouracil (5-FU) and leucovorin (LV) with oxaliplatin, mainly FOLFOX regimens, has shown considerable antitumor activity and a tolerable toxicity profile in gastric cancer. The goal of this study was to retrospectively compare the efficacy and toxicity of modified FOLFOX-6 (mFOLFOX6) regimen in advanced gastric cancer (AGC) patients with good and poor performance status (PS). Materials and Methods: AGC patients receiving the mFOLFOX6 regimen including oxaliplatin $85mg/m^2$, bolus of 5-FU $400mg/m^2$ and LV $400mg/m^2$ on the first day, followed by $2400mg/m^2$ of 5- FU as a continious infusion over 46 hour for first-line treatment were eligible for the study. Results: A total 58 patients with a median age of 59.5 (32-81) were included. The median follow up of the study was 9.2 months. Thirty patients (51.7%) with an ECOG PS 0-1 were assigned to the good PS arm, while 28 patients (48.3%) with ECOG PS 2 were in the poor PS arm. Overall response rates were 36.6 and 28.8%, respectively (p=0.91). Median PFS was 6.7 and 6.3 months in good PS and poor PS arms (p=0.50) and median OS was 9.6 and 10.4 months (p=0.55). As compared with good PS arm, poor PS arm was associated with more grade 3-4 neutropenia and anemia. Dose reduction and dose delays were also significantly higher. Conclusions: In this study, mFOLFOX6 was similarly effective in both arms. Although hematologic toxicity was significantly higher in patients with poor PS, it remained manageable. Our results suggest that this regimen may be an effective treatment option for AGC patients with poor PS.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권1호
• /
• pp.423-427
• /
• 2013

Background: Phase II and III trials of docetaxel, cisplatin and fluorouracil (DCF) have shown superior efficacy versus cisplatin and fluorouracil alone but with high rates of hematologic toxicity in metastatic gastric cancer cases. To reduce toxicity while maintaining the efficacy of DCF, we investigated low dose docetaxel (D), cispatin (C) - leucovorin and fluorouracil (De Gramont regimen). Patient and methods: Chemotherapy-naïve patients with metastatic gastric cancer (MGC) received D 60 mg/$m^2$ on day 1 and cisplatin 30 mg/$m^2$ on day 1-2 and the De Gramont regimen (Folinic acid 400 mg/m2 on day 1 and 5-FU 2400 mg/$m^2$/46h continuous infusion) every 3 weeks. The primary endpoint was response rate. Results: One hundred twenty patients with a median age of 52.5 years (range, 32-78) received a median of 6 cycles (range, 2-12 cycles). Of the 120 evaluable patients, 4 showed complete remission and 36 achieved a partial response. The overall response rate was 56.6%. Twenty eight patients (23.3%) showed stable disease and 52 (43.3%) progression. The median time to progression was 7 months (95%CI 6-7.9). The median overall survival was 15 months (95%CI 13.7-16.2). The most frequent hematological toxicity was leucopenia, which occurred at grade 3/4 intensity in 24 patients (20%). Conclusions: Low-dose DC-De Gramont regimen is active in MGC with a tolerable toxicity profile.

• 한국임상수의학회지
• /
• 제30권5호
• /
• pp.387-389
• /
• 2013

8년령의 중성화하지 않은 암컷 시츄견이 자궁축농증을 치료받기 위해 충남대학교 부속동물병원에 내원하였다. 임상증상으로 질출혈, 외음부출혈, 다식, 다음/다뇨 및 구토 등이 있었다. 혈액검사상으로는 미약한 백혈구감소증이 있었고 혈청화학적으로 ALP 감소 및 GLU 증가가 있었다. 방사선, 초음파 및 복강천자로 이루어졌으며 자궁축농증에 의한 복막염으로 잠정 진단하였다. 수술적 처치로 난소자궁적출술을 실시하였으며 생리식염수로 복강을 세척하였다. 심산 장 괴사가 있었고 자궁축농증에 의한 난소간막에서 농의 복강내로의 유출이 있었다. 이번 보고에서 2차적으로 패혈성 복막염이 발병할 수 있으니 자궁축농증 진단 시 2차성 질병에 대해서도 고려되어야 할 것이다.